PMID- 38520612
OWN - NLM
STAT- Publisher
LR  - 20240323
IS  - 1863-4362 (Electronic)
IS  - 0021-1265 (Linking)
DP  - 2024 Mar 23
TI  - Association between chitinase-3-like protein 1 and metabolic-associated fatty 
      liver disease in patients with type 2 diabetes mellitus.
LID - 10.1007/s11845-024-03671-z [doi]
AB  - BACKGROUND AND AIM: Early identification of liver fibrosis is essential for the 
      prognosis of metabolic-associated fatty liver disease (MAFLD), particularly in 
      type 2 diabetes mellitus (T2DM) patients. Here, we explored the association of 
      chitinase-3-like protein 1 (CHI3L1) and liver fibrosis in T2DM-MAFLD patients. 
      METHODS: Liver fibrosis was staged in T2DM-MAFLD patients, and a liver stiffness 
      measurement (LSM) of >/= 8 kPa was used to differentiate between non-significant 
      (NSLF) and significant liver fibrosis (SLF) subgroups. The two subgroups were 
      compared for serum CHI3L1 and other parameters. Linear correlation, logistic 
      regression, and restricted cubic spline (RCS) analyses were performed to evaluate 
      the association between CHI3L1 and liver fibrosis. Receiver operating 
      characteristic (ROC) curve analysis was performed to assess the diagnostic 
      accuracy of CHI3L1. RESULTS: Among T2DM-MAFLD, SLF patients had higher CHI3L1 
      compared to NSLF patients. CHI3L1 was found to be positively correlated with LSM. 
      Multivariate logistic regression analysis suggested that CHI3L1 may be a 
      potential independent risk factor for SLF. Further stratified analysis indicated 
      that the odds ratios of SLF in the high CHI3L1 group were higher than in the low 
      CHI3L1 group in the subgroups. RCS analysis suggested an increasing trend in the 
      incidence of significant fibrosis with the rising level of CHI3L1. The area under 
      the ROC curve for detecting significant fibrosis was 0.749 (95% CI: 0.668-0.829). 
      CONCLUSIONS: Serum CHI3L1 demonstrates an association with significant liver 
      fibrosis. High serum levels of CHI3L1 may indicate the existence of significant 
      liver fibrosis in T2DM-MAFLD patients.
CI  - (c) 2024. The Author(s), under exclusive licence to Royal Academy of Medicine in 
      Ireland.
FAU - Zhang, Fan
AU  - Zhang F
AD  - Department of Endocrinology, Changzhou Third People's Hospital, Changzhou Medical 
      Center, Nanjing Medical University, Changzhou, China.
AD  - Department of Clinical Nutrition, Changzhou Third People's Hospital, Changzhou 
      Medical Center, Nanjing Medical University, Changzhou, China.
FAU - Han, Yan
AU  - Han Y
AD  - Department of Endocrinology, Changzhou Third People's Hospital, Changzhou Medical 
      Center, Nanjing Medical University, Changzhou, China.
AD  - Department of Clinical Nutrition, Changzhou Third People's Hospital, Changzhou 
      Medical Center, Nanjing Medical University, Changzhou, China.
FAU - Zheng, Liming
AU  - Zheng L
AD  - Clinical Laboratory, Changzhou Third People's Hospital, Changzhou Medical Center, 
      Nanjing Medical University, Changzhou, China.
FAU - Bao, Zuowei
AU  - Bao Z
AD  - Department of Ultrasonography, Changzhou Third People's Hospital, Changzhou 
      Medical Center, Nanjing Medical University, Changzhou, China.
FAU - Liu, Longgen
AU  - Liu L
AD  - Department of Liver Diseases, Changzhou Third People's Hospital, Changzhou 
      Medical Center, Nanjing Medical University, Changzhou, China. ssewllg@163.com.
FAU - Li, Wenjian
AU  - Li W
AUID- ORCID: 0000-0002-7650-8842
AD  - Department of Urology, Changzhou Third People's Hospital, Changzhou Medical 
      Center, Nanjing Medical University, Changzhou, China. bolite@163.com.
LA  - eng
GR  - CJ20200059/Natural Science Foundation of Changzhou Municipality (CN)/
GR  - Key Talents Project/Changzhou Third People's Hospital/
GR  - ZD202119/Changzhou Health Commission/
PT  - Journal Article
DEP - 20240323
PL  - Ireland
TA  - Ir J Med Sci
JT  - Irish journal of medical science
JID - 7806864
SB  - IM
OTO - NOTNLM
OT  - Chitinase-3-like protein 1
OT  - Liver fibrosis
OT  - Metabolic-associated fatty liver disease
OT  - Type 2 diabetes mellitus
EDAT- 2024/03/23 20:51
MHDA- 2024/03/23 20:51
CRDT- 2024/03/23 12:20
PHST- 2023/09/29 00:00 [received]
PHST- 2024/03/15 00:00 [accepted]
PHST- 2024/03/23 20:51 [medline]
PHST- 2024/03/23 20:51 [pubmed]
PHST- 2024/03/23 12:20 [entrez]
AID - 10.1007/s11845-024-03671-z [pii]
AID - 10.1007/s11845-024-03671-z [doi]
PST - aheadofprint
SO  - Ir J Med Sci. 2024 Mar 23. doi: 10.1007/s11845-024-03671-z.